evaluating clinical research (Record no. 58416)

MARC details
000 -LEADER
fixed length control field 04657nam a22004455i 4500
001 - CONTROL NUMBER
control field 978-0-387-72899-5
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250710084016.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 100301s2007 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9780387728995
-- 99780387728995
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-0-387-72899-5
Source of number or code doi
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 519.5
Edition information 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Furberg, Bengt D.
Relator term author.
245 10 - TITLE STATEMENT
Title evaluating clinical research
Medium [recurso electrónico] :
Remainder of title All that glitters is not gold /
Statement of responsibility, etc. by Bengt D. Furberg, Curt D. Furberg.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture New York, NY :
Name of producer, publisher, distributor, manufacturer Springer New York,
Date of production, publication, distribution, manufacture, or copyright notice 2007.
300 ## - PHYSICAL DESCRIPTION
Extent V, 165 p.
Other physical details online resource.
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term recurso en línea
Carrier type code cr
Source rdacarrier
347 ## - DIGITAL FILE CHARACTERISTICS
File type text file
Encoding format PDF
Source rda
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note What is the purpose of this book? -- Why is benefit-to-harm balance essential to treatment decisions? -- What are the strengths of randomized controlled clinical trials? -- What are the weaknesses of randomized controlled clinical trials? -- Do meta-analyses provide the ultimate truth? -- What are the strengths of observational studies? -- What are the weaknesses of observational studies? -- Were the scientific questions stated in advance? -- Were the treatment groups comparable initially? -- Why is blinding/masking so important? -- How is symptomatic improvement measured? -- Is it really possible to assess quality of life? -- What is the value of biologic markers in drug evaluation? -- How are adverse drug reactions measured? -- How representative are study subjects in clinical trials? -- What happened to the study subjects who disappeared from the analysis? -- How reliable are active-control trials? -- How informative are composite outcomes? -- Do changes in biologic markers predict clinical benefit? -- How trustworthy are the authors? -- Does publication in a reputable scientific journal guarantee quality? -- Is it necessary to be a biostatistician to interpret scientific data? -- Are all drugs of a class interchangeable? -- How much confidence can be placed on economic analysis? -- How should I handle the massive flow of information? -- How well is research translated into clinical care?.
520 ## - SUMMARY, ETC.
Summary, etc. The objective of this book is to make its readers better informed and more critical consumers of clinical research to help them recognize the strengths and the weaknesses of scientific publications. In doing so, the reader will be able to distinguish patient-important and methodologically sound studies from those having limitations in design, conduct and interpretation. There are no prerequisites for reading this book. The text is basic and has no statistical formulas. Key take-home messages are listed at the end of each chapter. The large number of cartoons has two purposes: First, to make the text easier to read and generate a few laughs and, second, to underscore specific points, sometimes in a provocative way. Bengt D. Furberg, MD, PhD is board-certified in internal medicine. After spending a decade as medical director in the pharmaceutical industry, he now serves as medical consultant, evaluating the safety and efficacy of pharmaceutical products and medical devices and promoting evidence-based medicine. His brother, Curt D. Furberg, MD, PhD, is Professor in the Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA. After arriving in the United States from Sweden, he worked at the National Heart, Lung, and Blood Institute of the National Institutes of Health for 12 years. He is co-author of Fundamentals of Clinical Trials with Lawrence M. Friedman and David L. DeMets. His areas of interest are clinical trials, evidence-based medicine and drug safety. The authors have acquired much of their knowledge about clinical studies through the "trial and error" method. Thus, they have personal experience with many of the problems they describe.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element STATISTICS.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element TOXICOLOGY.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element QUALITY OF LIFE.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element QUALITY OF LIFE
General subdivision RESEARCH.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element STATISTICS.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element STATISTICS FOR LIFE SCIENCES, MEDICINE, HEALTH SCIENCES.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element QUALITY OF LIFE RESEARCH.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element PHARMACOLOGY/TOXICOLOGY.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Furberg, Curt D.
Relator term author.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Printed edition:
International Standard Book Number 9780387728988
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://dx.doi.org/10.1007/978-0-387-72899-5">http://dx.doi.org/10.1007/978-0-387-72899-5</a>
Public note Ver el texto completo en las instalaciones del CICY
912 ## -
-- ZDB-2-SMA
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Dewey Decimal Classification
Koha item type Libros electrónicos
Holdings
Lost status Source of classification or shelving scheme Damaged status Not for loan Collection Home library Current library Shelving location Date acquired Total checkouts Full call number Date last seen Price effective from Koha item type
  Dewey Decimal Classification     Libro electrónico CICY CICY Libro electrónico 10.07.2025   519.5 10.07.2025 10.07.2025 Libros electrónicos